Clinical Trial Update: A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders [Phase 3]

View source ↗

Summary

Phase 3 trial comparing swallowed Flovent (fluticasone) to placebo in eosinophilic esophagitis; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• Flovent (fluticasone propionate)

Snippet

Sponsor: Marc Rothenberg | Conditions: Eosinophilic Esophagitis | Phase 3 | Status: COMPLETED